




# PHARMACEUTICAL 2023

IGM Biosciences Inc.  
Rank 232 of 446





## PHARMACEUTICAL 2023

IGM Biosciences Inc.  
Rank 232 of 446

The relative strengths and weaknesses of IGM Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IGM Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 50% points. The greatest weakness of IGM Biosciences Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 69% points.

The company's Economic Capital Ratio, given in the ranking table, is 74%, being 31% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	438,421
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	44,685
Liabilities, Non-Current	35,356
Other Assets	41,594
Other Compr. Net Income	-635
Other Expenses	0
Other Liabilities	146,195
Other Net Income	7,923
Other Revenues	0
Property and Equipment	33,484
Research and Development	179,289
Selling, General and Administrative Expense	49,736

Output Variable	Value in 1000 USD
Assets	513,499
Liabilities	226,236
Expenses	229,025
Revenues	0
Stockholders Equity	287,263
Net Income	-221,102
Comprehensive Net Income	-221,420
Economic Capital Ratio	74%